Eli Lilly and Company (NYSE: LLY) reported second quarter 2023 earnings results today. Revenue increased 28% to $8.3 billion compared to the
Categories
pharmaceuticals
AMGN Earnings: Everything you need to know about Amgen’s Q2 results
Amgen Inc. (NASDAQ: AMGN) on Friday reported higher revenues and adjusted earnings for the second quarter of 2023. The biotechnology firm also
Gilead Sciences (GILD) Earnings: 2Q23 Key Numbers
Gilead Sciences, Inc. (NASDAQ: GILD) reported total revenue of $6.6 billion for the second quarter of 2023, which was up 5% year-over-year.
Cigna Corporation Q2 2023 Earnings Conference Call Insights
Key highlights from Cigna Corporation (CI) Q2 2023 Earnings Concall Q&A Highlights: [00:21:37] Scott Fidel with Stephens asked how are underlying utilization
REGN Earnings: Regeneron Pharma reports higher Q2 profit and revenue
Healthcare firm Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Thursday reported an increase in adjusted earnings and revenues for the second quarter of
Moderna, Inc Q2 2023 Earnings Conference Call Insights
Key highlights from Moderna, Inc (MRNA) Q2 2023 Earnings Concall Management Update: [00:16:30] MRNA’s COVID sales expectations for 2023 are in the
CI Earnings: A snapshot of Cigna’s Q2 2023 financial results
Healthcare company The Cigna Group (NYSE: CI) on Thursday reported a 7% increase in revenues for the second quarter of 2023. The
Infographic: Moderna (MRNA) Q2 2023 Earnings Results
Moderna, Inc. (NASDAQ: MRNA) reported second quarter 2023 earnings results today. Total revenue dropped to $344 million from $4.7 billion in the
Earnings Summary: A snapshot of McKesson Corporation’s Q1 2024 report
McKesson Corporation (NYSE: MCK), a diversified healthcare service company that operates in partnership with biopharma companies, care providers, pharmacies, and governments, on
CVS Health Corporation Q2 2023 Earnings Conference Call Insights
Key highlights from CVS Health Corporation (CVS) Q2 2023 Earnings Concall Management Update: [00:14:22] CVS said its restructuring efforts are expected to
Vertex Pharmaceuticals (VRTX) Earnings: 2Q23 Key Numbers
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported product revenue of $2.49 billion for the second quarter of 2023, which was up 14% year-over-year. Net
CVS Health Q2 2023 earnings drop despite higher revenues
Healthcare conglomerate CVS Health Corporation (NYSE: CVS) announced second-quarter 2023 results, reporting lower earnings despite an increase in revenues. June quarter adjusted
AmerisourceBergen Corporation (ABC) Q3 2023 Earnings Summary
AmerisourceBergen Corporation (NYSE: ABC) reported third quarter 2023 earnings results today. Revenue increased 11.5% year-over-year to $66.9 billion. Net income attributable to
Key takeaways from Pfizer’s (PFE) Q2 2023 earnings report
Shares of Pfizer Inc. (NYSE: PFE) were down over 1% on Tuesday after the company delivered mixed results for the second quarter
Merck & Co., Inc. Q2 2003 Earnings Conference Call Insights
Key highlights from Merck & Co., Inc. (MRK) Q2 2023 Earnings Concall Management Update: [00:18:54] MRK said it will continue to prioritize
Infographic: Key highlights from Merck’s (MRK) Q2 2023 earnings results
Merck (NYSE: MRK) reported second quarter 2023 earnings results today. Total worldwide sales were $15 billion, up 3% from the same period
PFE Earnings: All you need to know about Pfizer’s Q2 2023 earnings results
Pfizer Inc. (NYSE: PFE) reported second quarter 2023 earnings results today. Revenues decreased 54% year-over-year to $12.7 billion. Reported net income declined
Earnings Summary: All you need to know about DexCom’s Q2 report
Healthcare company DexCom, Inc. (NASDAQ: DXCM) reported a double-digit increase in second-quarter earnings and also provided full-year guidance. Second-quarter revenue grew 25%
BSX Earnings: Highlights of Boston Scientific’s Q2 2023 results
Medical device maker Boston Scientific Corporation (NYSE: BSX) reported financial results for the second quarter of 2023. The company also provided guidance for
BMY Earnings: A snapshot of Bristol-Myers Squibb’s Q2 2023 results
Biotechnology company Bristol Myers Squibb (NYSE: BMY) on Thursday said its second-quarter adjusted earnings decreased year-over-year, hurt by a fall in revenues.
BIIB Earnings: A snapshot of Biogen’s Q2 2023 financial results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the second quarter of 2023. Total